Regencell Bioscience Holdings Limited RGC
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 234.90% | 234.90% | -30.89% | -30.89% | -19.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 170.02% | 170.02% | -26.09% | -26.09% | -14.45% |
| Operating Income | -170.02% | -170.02% | 26.09% | 26.09% | 14.45% |
| Income Before Tax | -186.90% | -186.90% | 20.52% | 20.52% | 15.20% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -186.90% | -186.90% | 20.52% | 20.52% | 15.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -186.90% | -186.90% | 22.58% | 22.58% | 10.31% |
| EBIT | -170.02% | -170.02% | 26.09% | 26.09% | 14.45% |
| EBITDA | -175.16% | -175.16% | 22.83% | 28.05% | 11.05% |
| EPS Basic | -184.21% | -184.21% | 26.09% | 26.09% | 9.52% |
| Normalized Basic EPS | -183.33% | -183.33% | 29.41% | 29.41% | -- |
| EPS Diluted | -184.21% | -184.21% | 26.09% | 26.09% | 9.52% |
| Normalized Diluted EPS | -183.33% | -183.33% | 29.41% | 29.41% | -- |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |